Literature DB >> 27057737

The TLR-specific adjuvants R-848 and CpG-B endorse the immunological reaction of neonatal antigen-presenting cells.

Simone Schüller1, Lukas Wisgrill1, Kambis Sadeghi1, Erich Gindl1, Hanns Helmer2, Peter Husslein2, Angelika Berger1, Andreas Spittler3, Elisabeth Förster-Waldl1.   

Abstract

BACKGROUND: Preterm neonates display an impaired vaccine response. Neonatal antigen-presenting cells (APCs) are less effective to induce an adaptive immune response and to promote the development of immunological memory. Efficient adjuvantal toll-like receptor (TLR)-triggering may overcome the neonatal immunological impairment. Accordingly, the aim of this study was to investigate the immunostimulatory action of R-848 and CpG-B on neonatal APCs.
METHODS: Surface marker and cytokine secretion of APCs were evaluated after incubation of cord blood and peripheral blood mononuclear cells with the indicated adjuvants and were analyzed using flow cytometry.
RESULTS: TLR-specific stimulation resulted in a significant induction of costimulatory molecules on neonatal APCs. Stimulation with R-848 resulted in significant higher secretion of TNFα, IL-6, IL-10, IL-12/IL-23p40, IL-12p70, and IFN-γ. Interestingly, CpG-B resulted in significant higher secretion of TNFα and IL-6.
CONCLUSION: In summary, the incubation of TLR-agonists induced activation and maturation of neonatal APCs. These data show that modern TLR-specific adjuvants achieve a direct effect and potent upregulation of activation and maturation markers and cytokines in preterm neonates. We thus conclude that agents triggering TLRs might possibly overcome neonatal lack of vaccine responses.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27057737     DOI: 10.1038/pr.2016.71

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  34 in total

1.  Immunogenicity of trivalent influenza vaccine in extremely low-birth-weight, premature versus term infants.

Authors:  Carl T D'Angio; Roy J Heyne; Shahnaz Duara; Lucy C Holmes; T Michael O'Shea; Hongyue Wang; Dongwen Wang; Pablo J Sánchez; Robert C Welliver; Rita M Ryan; Kenneth C Schnabel; Caroline B Hall
Journal:  Pediatr Infect Dis J       Date:  2011-07       Impact factor: 2.129

Review 2.  Alum adjuvant: some of the tricks of the oldest adjuvant.

Authors:  Mirjam Kool; Kaat Fierens; Bart N Lambrecht
Journal:  J Med Microbiol       Date:  2011-12-15       Impact factor: 2.472

3.  Monocyte toll-like receptor 4 expression and LPS-induced cytokine production increase during gestational aging.

Authors:  Elisabeth Förster-Waldl; Kambis Sadeghi; Dietmar Tamandl; Bernadette Gerhold; Ulrike Hallwirth; Klaudia Rohrmeister; Michael Hayde; Andrea R Prusa; Kurt Herkner; George Boltz-Nitulescu; Arnold Pollak; Andreas Spittler
Journal:  Pediatr Res       Date:  2005-05-05       Impact factor: 3.756

Review 4.  Immunisation of premature infants.

Authors:  J Bonhoeffer; C-A Siegrist; P T Heath
Journal:  Arch Dis Child       Date:  2006-11       Impact factor: 3.791

5.  CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults.

Authors:  Curtis L Cooper; Heather L Davis; Jonathan B Angel; Mary Lou Morris; Sue M Elfer; Isabelle Seguin; Arthur M Krieg; D William Cameron
Journal:  AIDS       Date:  2005-09-23       Impact factor: 4.177

6.  Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer.

Authors:  Sylvia Adams; Lina Kozhaya; Frank Martiniuk; Tze-Chiang Meng; Luis Chiriboga; Leonard Liebes; Tsivia Hochman; Nicholas Shuman; Deborah Axelrod; James Speyer; Yelena Novik; Amy Tiersten; Judith D Goldberg; Silvia C Formenti; Nina Bhardwaj; Derya Unutmaz; Sandra Demaria
Journal:  Clin Cancer Res       Date:  2012-07-05       Impact factor: 12.531

Review 7.  Neonatal and early life vaccinology.

Authors:  C A Siegrist
Journal:  Vaccine       Date:  2001-05-14       Impact factor: 3.641

Review 8.  Vaccination in the neonatal period and early infancy.

Authors:  C A Siegrist
Journal:  Int Rev Immunol       Date:  2000       Impact factor: 5.311

9.  A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults.

Authors:  Issaka Sagara; Ruth D Ellis; Alassane Dicko; Mohamed B Niambele; Beh Kamate; Ousmane Guindo; Mahamadou S Sissoko; Michael P Fay; Merepen A Guindo; Ousmane Kante; Renion Saye; Kazutoyo Miura; Carole Long; Gregory E D Mullen; Mark Pierce; Laura B Martin; Kelly Rausch; Amagana Dolo; Dapa A Diallo; Louis H Miller; Ogobara K Doumbo
Journal:  Vaccine       Date:  2009-10-27       Impact factor: 3.641

10.  Prevalence of Helicobacter pylori infection and atrophic gastritis in Latvia.

Authors:  Marcis Leja; Eva Cine; Dace Rudzite; Ilona Vilkoite; Teppo Huttunen; Ilva Daugule; Ingrida Rumba-Rozenfelde; Sergey Pimanov; Inta Liepniece-Karele; Jelena Pahomova; Karlis Purmalis; Janis Eglitis; Valdis Pirags; Vilnis Dzerve; Andrejs Erglis
Journal:  Eur J Gastroenterol Hepatol       Date:  2012-12       Impact factor: 2.566

View more
  7 in total

1.  Endothelial cells of extremely premature infants display impaired immune response after proinflammatory stimulation.

Authors:  Lukas Wisgrill; Martina Muck; Isabelle Wessely; Angelika Berger; Andreas Spittler; Elisabeth Förster-Waldl; Kambis Sadeghi
Journal:  Pediatr Res       Date:  2017-09-27       Impact factor: 3.756

2.  Modified Fe3O4 Magnetic Nanoparticle Delivery of CpG Inhibits Tumor Growth and Spontaneous Pulmonary Metastases to Enhance Immunotherapy.

Authors:  Xueyan Zhang; Fengbo Wu; Ke Men; Rong Huang; Bailin Zhou; Rui Zhang; Rui Zou; Li Yang
Journal:  Nanoscale Res Lett       Date:  2018-08-17       Impact factor: 4.703

3.  CpG Oligonucleotides Protect Mice From Alphavirus Encephalitis: Role of NK Cells, Interferons, and TNF.

Authors:  Mohanraj Manangeeswaran; Aaron P Lewkowicz; Tomer Israely; Derek D C Ireland; Daniela Verthelyi
Journal:  Front Immunol       Date:  2020-02-18       Impact factor: 7.561

4.  Diminished secretion and function of IL-29 is associated with impaired IFN-α response of neonatal plasmacytoid dendritic cells.

Authors:  Lukas Wisgrill; Isabelle Wessely; Antonia Netzl; Linda Pummer; Kambis Sadeghi; Andreas Spittler; Angelika Berger; Elisabeth Förster-Waldl
Journal:  J Leukoc Biol       Date:  2019-06-18       Impact factor: 4.962

5.  OVA-PEG-R848 nanocapsules stimulate neonatal conventional and plasmacytoid dendritic cells.

Authors:  Sebastian Wirsching; Marina Machtakova; Frauke Borgans; Leah Pretsch; Michael Fichter; Maximiliano L Cacicedo; Héloïse Thérien-Aubin; Katharina Landfester; Stephan Gehring
Journal:  Front Pediatr       Date:  2022-09-13       Impact factor: 3.569

Review 6.  Immunomodulation to Prevent or Treat Neonatal Sepsis: Past, Present, and Future.

Authors:  Simone S Schüller; Boris W Kramer; Eduardo Villamor; Andreas Spittler; Angelika Berger; Ofer Levy
Journal:  Front Pediatr       Date:  2018-07-19       Impact factor: 3.418

Review 7.  Modulating Immune Response with Nucleic Acid Nanoparticles.

Authors:  Jake K Durbin; Daniel K Miller; Julia Niekamp; Emil F Khisamutdinov
Journal:  Molecules       Date:  2019-10-17       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.